17 recruiting, 10 completed, 6 unknown, 3 active not recruiting. 35 Phase 1, 16 Phase 2, 1 Early Phase 1.
Follow Locally Advanced or Metastatic Solid Tumors: new trials by email Literature Review of Locally Advanced or Metastatic Solid Tumors trials Research Report on Locally Advanced or Metastatic Solid Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of RO7821657 in Participants With Solid Tumors RO7821657 - Locally Advanced or Metastatic Solid Tumors | Phase 1 | Not yet recruiting | Hoffmann-La Roche | 405 | 2026-10-26 | 2026-10-20 |
| A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors ASP388B, Pembrolizumab, Carboplatin - Locally Advanced or Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Astellas Pharma Global Development, Inc. | 392 | 2026-09-02 | 2026-10-26 |
| A First-in-human Phase I Study to Evaluate EMB-15 in Patients With Locally Advanced or Metastatic Solid Tumors. EMB-15 - Locally Advanced or Metastatic Solid Tumors | Phase 1 | Recruiting | Shanghai EpimAb Biotherapeutics Co., Ltd. | 50 | 2026-05-26 | 2026-06-15 |
| A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression CVL237 tablets - Locally Advanced or Metastatic Solid Tumors, PTEN Loss or Low Expression | Phase 2 | Not yet recruiting | Convalife (Shanghai) Co., Ltd. | 180 | 2026-05-01 | 2026-03-03 |
| BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors BC3195, Pembrolizumab/KEYTRUDA® - Locally Advanced or Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Biocity Biopharmaceutics Co., Ltd. | 111 | 2026-03-31 | 2026-05-28 |
| Phase 2 Clinical Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GH21 Capsules Combined With D-1553 Tablets in Subjects With Locally Advanced or Metastatic Solid Tumors With the KRASG12C Mutation GH21，D-1553 - Locally Advanced or Metastatic Solid Tumors | Phase 2 | Not yet recruiting | Suzhou Genhouse Bio Co., Ltd. | 120 | 2025-12-30 | 2026-01-06 |
| A Study of YL202 in Patients With Advanced Solid Tumors YL202 - Non Small Cell Lung Cancer, Colorectal Cancer | Phase 2 | Recruiting | MediLink Therapeutics (Suzhou) Co., Ltd. | 100 | 2025-08-04 | 2026-10-14 |
| A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors MRG007, MRG007 and Bevacizumab - Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer | Phase 1 | Recruiting | ArriVent BioPharma, Inc. | 572 | 2025-07-25 | 2026-08-13 |
| Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors IBI3005 - Unresectable, Locally Advanced or Metastatic Solid Tumors | Phase 1 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 198 | 2025-01-08 | 2025-01-22 |
| A Study to Evaluate the Safety, Tolerability, PK, PD, and Preliminary Efficacy of CS01 in Patients With Locally Advanced or Metastatic Solid Tumors CS01 (an anti-OX40 antibody) - Locally Advanced or Metastatic Solid Tumors | Phase 1 / Phase 2 | Active not recruiting | Ruijin Hospital | 10 | 2024-12-30 | 2026-03-10 |
| Study of XB010 in Subjects With Solid Tumors XB010, Pembrolizumab - Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer | Phase 1 | Recruiting | Exelixis | 396 | 2024-08-06 | 2026-10-30 |
| A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors ANS014004 - Locally Advanced or Metastatic Solid Tumors | Phase 1 | Recruiting | Avistone Biotechnology Co., Ltd. | 63 | 2024-06-24 | 2026-04-17 |
| A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors ANS014004 - Locally Advanced or Metastatic Solid Tumors | Phase 1 | Active not recruiting | Avistone Biotechnology Co., Ltd. | 40 | 2024-05-19 | 2026-03-25 |
| A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors BL-M05D1 - Locally Advanced or Metastatic Solid Tumors | Phase 1 | Recruiting | Biokin (Shanghai) Biopharmaceutical Co., Ltd. | 30 | 2024-04-19 | 2026-11-02 |
| Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors DA-4505, DA-4505 + Pembrolizumab - Locally Advanced or Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Dong-A ST Co., Ltd. | 125 | 2024-04-18 | 2025-02-12 |
| PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors PTT-936, Combination of PTT-936 and anti-PD-1/L1 therapy - Locally Advanced or Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Pyrotech Therapeutics, Inc. | 68 | 2024-01-26 | 2026-08-10 |
| A Study of TYK-00540 in Adult Patients With Solid Tumors TYK-00540 - Locally Advanced or Metastatic Solid Tumors | Phase 1 | Recruiting | TYK Medicines, Inc | 156 | 2024-01-02 | 2024-02-07 |
| A Study of YL202 in Selected Patients With Advanced Solid Tumors YL202 should be intravenously infused - NSCLC, Breast Cancer | Phase 2 | Recruiting | MediLink Therapeutics (Suzhou) Co., Ltd. | 200 | 2023-12-15 | 2025-11-26 |
| Clinical Study of SM3321 With Solid Tumors SM3321 - Locally Advanced or Metastatic Solid Tumors | Phase 1 | Completed | Beijing StarMab Biomed Technology Ltd | 7 | 2023-12-07 | 2026-07-23 |
| A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies AP203 - Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Recruiting | AP Biosciences Inc. | 168 | 2023-07-24 | 2025-03-26 |
Showing 20 of 42. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (6) · Squamous Cell Carcinoma of Head and Neck (4) · Stomach Neoplasms (4) · Colorectal Neoplasms (3) · Esophageal Squamous Cell Carcinoma (3) · Uterine Cervical Neoplasms (3) · Breast Neoplasms (2) · Esophageal Neoplasms (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Ovarian Neoplasms (2) · Small Cell Lung Carcinoma (2) · Triple Negative Breast Neoplasms (2) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1)
Neoplasms (12) · Neoplasms by Site (11) · Digestive System Diseases (8) · Digestive System Neoplasms (8) · Gastrointestinal Diseases (8) · Gastrointestinal Neoplasms (8) · Lung Diseases (8) · Respiratory Tract Diseases (8) · Respiratory Tract Neoplasms (8) · Thoracic Neoplasms (8) · Bronchial Neoplasms (7) · Carcinoma, Bronchogenic (7) · Lung Neoplasms (7) · Neoplasms by Histologic Type (6) · Carcinoma (5)
pembrolizumab (8) · atezolizumab (2) · toripalimab (2) · AZD 6244 (1) · Albumin-Bound Paclitaxel (1) · Bevacizumab (1) · Carboplatin (1) · Cetuximab (1) · Cyclophosphamide (1) · Fluorouracil (1) · Injections (1) · MK 2206 (1) · N-(2,3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamide (1) · Oxaliplatin (1) · Taxes (1)
Avistone Biotechnology Co., Ltd. (2) · Biocity Biopharmaceutics Co., Ltd. (2) · Chugai Pharmaceutical (2) · MediLink Therapeutics (Suzhou) Co., Ltd. (2) · Shanghai Henlius Biotech (2) · AP Biosciences Inc. (1) · Amphivena Therapeutics, Inc. (1) · Antengene Therapeutics Limited (1) · ArriVent BioPharma, Inc. (1) · Astellas Pharma Global Development, Inc. (1) · BeiGene (1) · Beijing StarMab Biomed Technology Ltd (1) · Bio-Thera Solutions (1) · Biokin (Shanghai) Biopharmaceutical Co., Ltd. (1) · CStone Pharmaceuticals (1)
China (23) · United States (12) · Australia (4) · Japan (4) · Spain (4) · United Kingdom (4) · Netherlands (3) · South Korea (3) · Belgium (2) · Canada (2) · France (2) · Taiwan (2) · Denmark (1) · Greece (1) · Hungary (1)
Dongmei Ji (1) · Elisabeth de Vries, Professor (1) · Ganessan Kichenadasse, MD (1) · Jin Li (1) · Jin Li, PhD (1) · Joo Hyuk Sohn, MD (1) · Lin Shen, PHD (1) · Lingying WU (1)
PMID 25516890, PMID 27483391, PMID 27934635, PMID 30478423, PMID 35522941, PMID 36394867, PMID 38970256, PMID 40490502, PMID 41737913, PMID 42012895, PMID 42722782
2017 (1), 2018 (1), 2019 (1), 2023 (1)